These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme. Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763 [TBL] [Abstract][Full Text] [Related]
8. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238 [TBL] [Abstract][Full Text] [Related]
9. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy. Lichterfeld M; Wöhrmann A; Schmeisser N; Fätkenheuer G; Salzberger B; Wyen C; Schmitz K; Sauerbruch T; Rockstroh JK Eur J Med Res; 2003 Feb; 8(2):56-60. PubMed ID: 12626282 [TBL] [Abstract][Full Text] [Related]
10. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. Miró JM; Manzardo C; Pich J; Domingo P; Ferrer E; Arribas JR; Ribera E; Arrizabalaga J; Loncá M; Cruceta A; de Lazzari E; Fuster M; Podzamczer D; Plana M; Gatell JM; AIDS Res Hum Retroviruses; 2010 Jul; 26(7):747-57. PubMed ID: 20624069 [TBL] [Abstract][Full Text] [Related]
11. Neutrophil peripheral count and human leukocyte elastase during chronic lithium carbonate therapy. Capodicasa E; Russano AM; Ciurnella E; De Bellis F; Rossi R; Scuteri A; Biondi R Immunopharmacol Immunotoxicol; 2000 Nov; 22(4):671-83. PubMed ID: 11105780 [TBL] [Abstract][Full Text] [Related]
12. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy. Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F; Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053 [TBL] [Abstract][Full Text] [Related]
13. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Jenny-Avital ER; Joseph K Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504 [TBL] [Abstract][Full Text] [Related]
14. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110 [TBL] [Abstract][Full Text] [Related]
15. In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis. Miró O; Villarroya J; Garrabou G; López S; Rodríguez de la Concepción M; Pedrol E; Martínez E; Giralt M; Gatell JM; Cardellach F; Casademont J; Villarroya F Antivir Ther; 2005; 10(8):945-51. PubMed ID: 16430200 [TBL] [Abstract][Full Text] [Related]
17. Protease inhibitors and rifabutin: isn't the jury still out? Jenny-Avital ER Clin Infect Dis; 2001 Jan; 32(2):322-3. PubMed ID: 11170931 [No Abstract] [Full Text] [Related]
18. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F; Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377 [TBL] [Abstract][Full Text] [Related]
19. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy. Müller AD; Myer L; Jaspan H Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495 [TBL] [Abstract][Full Text] [Related]